Role of combination therapy in the treatment of pulmonary arterial hypertension (Q37718231)

22 August 2017

1 reference

title

Role of combination therapy in the treatment of pulmonary arterial hypertension (English)

1 reference

22 August 2017

arterial hypertension

0 references

author name string

Teena Abraham

1

1 reference

22 August 2017

Gary Wu

2

1 reference

22 August 2017

Fabienne Vastey

3

1 reference

22 August 2017

Jonathan Rapp

4

1 reference

22 August 2017

Nasser Saad

5

1 reference

22 August 2017

Eric Balmir

6

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

30

1 reference

22 August 2017

4

1 reference

22 August 2017

390-404

1 reference

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

22 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Role of ambrisentan in the management of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Diagnosis and differential assessment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

A USA-based registry for pulmonary arterial hypertension: 1982-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Evaluation and management of the patient with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Bosentan for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Sildenafil for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.390

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.4.390

1 reference

22 August 2017

1 reference